Matching up treatments for chronic schizophrenia is a challenge
The pharmacologic options available for the treatment of schizophrenia have never been greater. Yet, clinicians face difficult choices when selecting antipsychotics as they weigh the drugs' risks and benefits. This dilemma was underscored recently when a federally funded study found that of five agents, the most efficacious one, olanzapine (Zyprexa, Lilly), also caused the most weight gain and metabolic changes that could lead to diabetes or heart disease.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
